1. Home
  2. URGN vs NWPX Comparison

URGN vs NWPX Comparison

Compare URGN & NWPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • NWPX
  • Stock Information
  • Founded
  • URGN 2004
  • NWPX 1966
  • Country
  • URGN United States
  • NWPX United States
  • Employees
  • URGN N/A
  • NWPX N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • NWPX Steel/Iron Ore
  • Sector
  • URGN Health Care
  • NWPX Industrials
  • Exchange
  • URGN Nasdaq
  • NWPX Nasdaq
  • Market Cap
  • URGN 465.9M
  • NWPX 449.0M
  • IPO Year
  • URGN 2017
  • NWPX 1995
  • Fundamental
  • Price
  • URGN $10.27
  • NWPX $49.78
  • Analyst Decision
  • URGN Strong Buy
  • NWPX Buy
  • Analyst Count
  • URGN 5
  • NWPX 2
  • Target Price
  • URGN $44.50
  • NWPX $47.50
  • AVG Volume (30 Days)
  • URGN 487.3K
  • NWPX 69.6K
  • Earning Date
  • URGN 03-13-2025
  • NWPX 03-03-2025
  • Dividend Yield
  • URGN N/A
  • NWPX N/A
  • EPS Growth
  • URGN N/A
  • NWPX 25.64
  • EPS
  • URGN N/A
  • NWPX 2.94
  • Revenue
  • URGN $89,363,000.00
  • NWPX $483,085,000.00
  • Revenue This Year
  • URGN $13.39
  • NWPX $13.22
  • Revenue Next Year
  • URGN $45.06
  • NWPX $0.28
  • P/E Ratio
  • URGN N/A
  • NWPX $16.93
  • Revenue Growth
  • URGN 15.64
  • NWPX 9.54
  • 52 Week Low
  • URGN $9.78
  • NWPX $28.04
  • 52 Week High
  • URGN $20.70
  • NWPX $57.76
  • Technical
  • Relative Strength Index (RSI)
  • URGN 39.53
  • NWPX 52.17
  • Support Level
  • URGN $10.12
  • NWPX $44.49
  • Resistance Level
  • URGN $10.96
  • NWPX $49.13
  • Average True Range (ATR)
  • URGN 0.57
  • NWPX 1.79
  • MACD
  • URGN -0.01
  • NWPX 0.32
  • Stochastic Oscillator
  • URGN 24.75
  • NWPX 75.79

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About NWPX Northwest Pipe Company

Northwest Pipe Co is a manufacturer of water-related infrastructure products. The company has two operating segments; Engineered Steel Pressure Pipe segment manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. These products are also used for hydroelectric power systems, wastewater systems, seismic resiliency, and other applications, and Precast Infrastructure and Engineered Systems segment manufacture stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration, and other environmental and engineered solutions.

Share on Social Networks: